Bayer Stock News

Annual Awards Program Recognizes Innovation in Agricultural & Food Technologies Around the Globe Annual Awards Program Recognizes Innovation in Agricultural & Food Technologies Around the Globe

Bayer said on Monday its Monsanto unit reached agreements in principle with more than 200 plaintiffs to resolve the so-called Sky Valley Education Center product liability cases related to the chemical PCB.

Bayer DE000BAY0017 kann einen wesentlichen Teil der US-Rechtsstreitigkeiten rund um die schon seit Jahrzehnten verbotene Umweltchemikalie PCB wohl schon bald hinter sich lassen.

Bayer DE000BAY0017 kann einen wesentlichen Teil der US-Rechtsstreitigkeiten rund um die schon seit Jahrzehnten verbotene Umweltchemikalie PCB wohl schon bald hinter sich lassen.

WHIPPANY, N.J.--(BUSINESS WIRE)-- #consumerhealth--Bayer's Aspirina, the #1 pain relief option in Mexico1, is now available for purchase in the United States, bringing a well-known brand to the Hispanic community. With a deep commitment to Hispanic consumers, Aspirina is poised to provide an accessible and effective solution for pain relief. As the Hispanic population in the U.S. continues to g...

LEVERKUSEN, Germany, Aug. 15, 2025 (GLOBE NEWSWIRE) -- LumenHaus, Germany's forefront innovator in smart home energy solutions, has officially signed as an Official Premium Partner of Bayer 04 Leverkusen for the 2025/26 season, marking the start of a collaboration that blends tradition, innovation, and sustainability. This partnership brings together LumenHaus' smart energy solutions with the d...

BERLIN & SAN DIEGO--(BUSINESS WIRE)--Bayer and Kumquat Biosciences Inc., a clinical-stage biotech company founded by pioneers of the KRAS pathway, today announced that they have entered into an exclusive global license and collaboration to develop and commercialize Kumquat's KRAS G12D inhibitor. Under the agreement, Kumquat is responsible for the initiation and completion of the Phase Ia study,...

German pharmaceutical group Bayer announced on Tuesday a deal worth up to $1.3 billion with Kumquat Biosciences to develop the U.S.-based oncology specialist's potential new cancer drug.